123 related articles for article (PubMed ID: 38761480)
1. Effect of mTOR inhibitors on the mortality and safety of patients with lymphangioleiomyomatosis on the lung transplantation waitlist: A retrospective cohort study.
Sakurai T; Kanou T; Funaki S; Fukui E; Kimura T; Ose N; Inoue Y; Shintani Y
Respir Investig; 2024 Jul; 62(4):657-662. PubMed ID: 38761480
[TBL] [Abstract][Full Text] [Related]
2. A survey of use of mTOR inhibitors in patients with lymphangioleiomyomatosis listed for lung transplant.
Warrior K; Leard LE; Nair AR; Gries CJ; Fisher AJ; Johnson SR; McCormack FX; Dilling DF
Respir Med; 2022; 195():106779. PubMed ID: 35276437
[TBL] [Abstract][Full Text] [Related]
3. Should mammalian target of rapamycin inhibitors be stopped in women with lymphangioleiomyomatosis awaiting lung transplantation?
El-Chemaly S; Goldberg HJ; Glanville AR
Expert Rev Respir Med; 2014 Dec; 8(6):657-60. PubMed ID: 25199529
[TBL] [Abstract][Full Text] [Related]
4. Experience of Lung Transplantation in Patients with Lymphangioleiomyomatosis at a Brazilian Reference Centre.
Baldi BG; Samano MN; Campos SV; de Oliveira MR; Junior JEA; Carraro RM; Teixeira RHOB; Minguini IP; Burlina R; Pato EZS; Carvalho CRR; Costa AN
Lung; 2017 Dec; 195(6):699-705. PubMed ID: 28823029
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of sirolimus in lymphangioleiomyomatosis.
McCormack FX; Inoue Y; Moss J; Singer LG; Strange C; Nakata K; Barker AF; Chapman JT; Brantly ML; Stocks JM; Brown KK; Lynch JP; Goldberg HJ; Young LR; Kinder BW; Downey GP; Sullivan EJ; Colby TV; McKay RT; Cohen MM; Korbee L; Taveira-DaSilva AM; Lee HS; Krischer JP; Trapnell BC; ;
N Engl J Med; 2011 Apr; 364(17):1595-606. PubMed ID: 21410393
[TBL] [Abstract][Full Text] [Related]
6. Lung transplantation for lymphangioleiomyomatosis.
Warrior K; Dilling DF
J Heart Lung Transplant; 2023 Jan; 42(1):40-52. PubMed ID: 36334961
[TBL] [Abstract][Full Text] [Related]
7. Lymphangioleiomyomatosis.
Doubková M; Štefániková M; Čan V; Merta Z; Svoboda M
Klin Onkol; 2019; 32(5):367-374. PubMed ID: 31610670
[TBL] [Abstract][Full Text] [Related]
8. Lung Transplantation for Lymphangioleiomyomatosis in Japan.
Ando K; Okada Y; Akiba M; Kondo T; Kawamura T; Okumura M; Chen F; Date H; Shiraishi T; Iwasaki A; Yamasaki N; Nagayasu T; Chida M; Inoue Y; Hirai T; Seyama K; Mishima M;
PLoS One; 2016; 11(1):e0146749. PubMed ID: 26771878
[TBL] [Abstract][Full Text] [Related]
9. Lung Transplantation for Lymphangioleiomyomatosis in a Single Japanese Institute, With a Focus on Late-onset Complications.
Nakagiri T; Shintani Y; Minami M; Inoue M; Funaki S; Kawamura T; Okumura M
Transplant Proc; 2015; 47(6):1977-82. PubMed ID: 26293084
[TBL] [Abstract][Full Text] [Related]
10. Mayo clinic experience of lung transplantation in pulmonary lymphangioleiomyomatosis.
Ussavarungsi K; Hu X; Scott JP; Erasmus DB; Mallea JM; Alvarez F; Lee AS; Keller CA; Ryu JH; Burger CD
Respir Med; 2015 Oct; 109(10):1354-9. PubMed ID: 26321137
[TBL] [Abstract][Full Text] [Related]
11. Single lung transplantation for lymphangioleiomyomatosis: a single-center experience in Japan.
Oishi H; Watanabe T; Matsuda Y; Noda M; Ejima Y; Saiki Y; Seyama K; Kondo T; Okada Y
Surg Today; 2018 Oct; 48(10):944-950. PubMed ID: 29808303
[TBL] [Abstract][Full Text] [Related]
12. Reduced risk of recurrent pneumothorax for sirolimus therapy after surgical pleural covering of entire lung in lymphangioleiomyomatosis.
Sakurai T; Arai T; Hirose M; Kojima K; Sakamoto T; Matsuda Y; Sugimoto C; Yoon HE; Inoue Y
Orphanet J Rare Dis; 2021 Nov; 16(1):466. PubMed ID: 34732225
[TBL] [Abstract][Full Text] [Related]
13. Lymphangioleiomyomatosis treatment with sirolimus.
Casanova A; María Girón R; Acosta O; Barrón M; Valenzuela C; Ancochea J
Arch Bronconeumol; 2011 Sep; 47(9):470-2. PubMed ID: 21440356
[TBL] [Abstract][Full Text] [Related]
14. Calcineurin-inhibitor free immunosuppression after lung transplantation - a single center case-control study in 51 patients converted to Mechanistic Target of Rapamycin (mTOR) inhibitors.
Gottlieb J; Fischer B; Schupp JC; Golpon H
PLoS One; 2023; 18(5):e0284653. PubMed ID: 37200246
[TBL] [Abstract][Full Text] [Related]
15. Favorable survival even with high disease-specific complication rates in lymphangioleiomyomatosis after lung transplantation-long-term follow-up of a Japanese center.
Kurosaki T; Otani S; Miyoshi K; Okazaki M; Sugimoto S; Suno M; Yamane M; Kobayashi M; Oto T; Toyooka S
Clin Respir J; 2020 Feb; 14(2):116-123. PubMed ID: 31729820
[TBL] [Abstract][Full Text] [Related]
16. Waiting time and mortality rate on lung transplant candidates in Japan: a single-center retrospective cohort study.
Hirama T; Akiba M; Watanabe T; Watanabe Y; Notsuda H; Oishi H; Niikawa H; Okada Y
BMC Pulm Med; 2021 Nov; 21(1):390. PubMed ID: 34844592
[TBL] [Abstract][Full Text] [Related]
17. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.
Taveira-DaSilva AM; Hathaway O; Stylianou M; Moss J
Ann Intern Med; 2011 Jun; 154(12):797-805, W-292-3. PubMed ID: 21690594
[TBL] [Abstract][Full Text] [Related]
18. Effect of beta-agonists on LAM progression and treatment.
Le K; Steagall WK; Stylianou M; Pacheco-Rodriguez G; Darling TN; Vaughan M; Moss J
Proc Natl Acad Sci U S A; 2018 Jan; 115(5):E944-E953. PubMed ID: 29339522
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis.
Ando K; Kurihara M; Kataoka H; Ueyama M; Togo S; Sato T; Doi T; Iwakami S; Takahashi K; Seyama K; Mikami M
Respir Investig; 2013 Sep; 51(3):175-83. PubMed ID: 23978644
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Effect of Sirolimus for Lymphangioleiomyomatosis Remaining in the Abdominopelvic Region After Lung Transplantation: A Case Report.
Ito T; Suno M; Sakamoto K; Yoshizaki Y; Yamamoto K; Nakanishi R; Hirano Y; Irie M; Kurosaki T; Otani S; Yamane M; Sugimoto S; Miyoshi K; Oto T
Transplant Proc; 2016; 48(1):271-4. PubMed ID: 26915883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
